Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$86.97 – $156.26
17% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.23B | $1.24B | $866.4M | $899.2M | $1.38B | $1.45B | $1.58B | $1.79B |
| Cost of revenue | $645.6M | $623.5M | $457.2M | $457.9M | $659.8M | $648.5M | $698.5M | $771.4M |
| Gross profit | $585.6M | $616.1M | $409.3M | $441.3M | $722.1M | $802.3M | $886.1M | $1.02B |
| Gross margin | 47.6% | 49.7% | 47.2% | 49.1% | 52.3% | 55.3% | 55.9% | 56.9% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $207.5M | $186.0M | $110.1M | $110.4M | $76.7M | $168.2M | $217.1M | $341.5M |
| EBITDA | $266.1M | $210.9M | $309.6M | $182.7M | $297.4M | $328.9M | $347.0M | $397.7M |
| Net income | $33.8M | $128.8M | −$85.3M | $70.0M | $311.0M | $93.4M | $136.8M | $237.1M |
| Net margin | 2.7% | 10.4% | -9.8% | 7.8% | 22.5% | 6.4% | 8.6% | 13.3% |
| EPS (diluted) | 0.54 | 2.29 | 4.50 | 1.49 | -3.36 | 2.05 | 3.39 | 6.07 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.9B | $7.94 | $7.93–$7.95 | 2 |
| 2027 | $2.1B | $9.05 | $8.99–$9.10 | 2 |
| 2028 | $2.2B | $10.58 | $10.54–$10.59 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds ATGE.
No tracked institution reports a position in ATGE as of their last filing.
No one on the platform has traded ATGE yet.
| $3.5B |
| — |
| LAURLaureate Education, Inc. | $36.07 | -0.81% | $5.0B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 16.2× earnings vs its 20.5× historical median P/E.
Fair value ≈ $124.64 · price $98.54 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$ATGE Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $1.21 down -26.22% YoY • Reported revenue of $487.03M up 4.50% YoY
View on StockTwits ↗Wall St is expecting 1.80 EPS for $ATGE Q3 [Reporting 04/30 AMC] http://www.estimize.com/intro/atge?chart=historical&metric_name=eps&utm_co
View on StockTwits ↗$ATGE if you want to be a nurse or go into health services, this company has a monopoly on the necessary education/licensing. combine with the upward trend in necessary elder care from boomers/gen x along with job displacement over the next 3-4 years due to AI and you have a recipe for massive gains.
View on StockTwits ↗$ATGE just reshaped its healthcare strategy — and Covista is the result. 👀 Covista is emerging from ATGE’s healthcare-focused overhaul, positioning itself as workforce infrastructure designed to ease America’s medical staffing shortage. A clear pivot with a clear mission. See how this transformation is shaping the new healthcare play 👉 https://www.zacks.com/stock/news/2836243/adtalem-rebrands-as-covista-with-focus-on-healthcare-workforce-needs?cid=sm-stocktwits-2-2836243-teaser-32297&ADID=SYND_STOCKTWITS_TWEET_2_2836243_TEASER_32297
View on StockTwits ↗Adtalem Global Education transforms into Covista — what it means for investors! 🚀 $ATGE will become Covista, aligning its operations with the rising demand for healthcare professionals. The move underscores Covista’s commitment to addressing the U.S. healthcare workforce crisis by expanding training capacities and supporting underserved students. Discover what this strategic shift means for the stock 👉 https://www.zacks.com/stock/news/2836243/adtalem-rebrands-as-covista-with-focus-on-healthcare-workforce-needs?cid=sm-stocktwits-2-2836243-body-32283&ADID=SYND_STOCKTWITS_TWEET_2_2836243_BODY_32283
View on StockTwits ↗$ATGE fraudulent company. Going below 100 easily 🩸🩸🩸🩸🩸🩸🩸
View on StockTwits ↗$ATGE Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $2.14 up 5.42% YoY • Reported revenue of $503.38M up 12.43% YoY • Adtalem expects fiscal year 2026 capital expenditures to include IT investments and new campus development, alongside approximately $4.5 million in new operating lease liabilities commencing in Q3 FY26.
View on StockTwits ↗$ATGE Earnings - Q2/2026 Revenue: $503.38M ✅ vs. $490.76M est. EPS: $2.43 ✅ vs. $2.27 est. Adtalem Global Education posts Q2 FY2026 results, marking the tenth straight quarter of enrollment growth with 97,000 students, up 6.3% year over year. The company raises FY2026 adjusted EPS guidance and maintains revenue guidance; Investor Day is set for Feb. 24, 2026. CEO Steve Beard says the firm is addressing healthcare workforce gaps at scale, embedding AI within programs, and returned $165 million of capital to shareholders.
View on StockTwits ↗$ATGE reports after the close, Estimize Consensus +0.03 EPS and +4.90M Revs compared to WS http://www.estimize.com/atge/fq2-2026?utm_conten
View on StockTwits ↗$ATGE I find myself a bag holder into ER. The company has beat 4 consecutive quarters. Yet, the latest beat led to a 30.86% drop in share price the next trading day. Anyone else holding too?
View on StockTwits ↗$LRN Thoughts on the upcoming ER? Price has consolidated between $60–$70 for three months, a clear indecision in the market. Notably, peers $LOPE and $ATGE are recovering faster. Is $LRN losing momentum, or is it just coiled for a breakout?"
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.